Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5475 in adults with pulmonary arterial hypertension
2020-001108-40Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing MK-5475 with Placebo (2 arms). Primary endpoint: Change from baseline in pulmonary vascular resistance at 12 weeks (Phase 2 cohort). Started Jan 2021; status: active.
02
Drugs
frespaciguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2020-001108-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001108-40.